Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
8.31
+0.15 (1.84%)
At close: Mar 10, 2026, 4:00 PM EDT
8.41
+0.10 (1.20%)
After-hours: Mar 10, 2026, 7:25 PM EDT
Personalis Employees
As of December 31, 2025, Personalis had 260 total employees, including 259 full-time and 1 part-time employees. The number of employees increased by 31 or 13.54% compared to the previous year.
Employees
260
Change (1Y)
31
Growth (1Y)
13.54%
Revenue / Employee
$267,877
Profits / Employee
-$312,577
Market Cap
869.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 260 | 31 | 13.54% | 259 | 1 |
| Dec 31, 2024 | 229 | 4 | 1.78% | 228 | 1 |
| Dec 31, 2023 | 225 | -174 | -43.61% | 223 | 2 |
| Dec 31, 2022 | 399 | 73 | 22.39% | 395 | 4 |
| Dec 31, 2021 | 326 | 91 | 38.72% | 325 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| GRAIL | 1,000 |
| Twist Bioscience | 979 |
| Castle Biosciences | 883 |
PSNL News
- 12 days ago - Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights - Business Wire
- 21 days ago - Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference - Business Wire
- 26 days ago - Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 weeks ago - Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance - Business Wire
- 5 weeks ago - Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors - Business Wire
- 5 weeks ago - Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Business Wire
- 2 months ago - Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™ - Business Wire